Insmed received FDA approval for Brinsupri (brensocatib), the first therapy approved for non-cystic fibrosis bronchiectasis (NCFB), a progressive lung disease impacting approximately 500,000 U.S. patients. Brinsupri, a dipeptidyl peptidase 1 (DPP1) inhibitor, targets neutrophilic inflammation—a key driver of bronchiectasis exacerbations. The drug offers once-daily oral dosing with two approved strengths, affording flexibility in clinical use. Insmed aims to expand regulatory submissions globally, projecting peak sales up to $5 billion. This approval marks a significant milestone for a disease lacking prior approved treatments.